lorenzo  trippa
lorenzo trippa
Harvard and Dana Farber
Email verificata su
Citata da
Citata da
Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis
LM Spring, G Fell, A Arfe, C Sharma, R Greenup, KL Reynolds, BL Smith, ...
Clinical cancer research 26 (12), 2838-2848, 2020
Bifurcation analysis of single-cell gene expression data reveals epigenetic landscape
E Marco, RL Karp, G Guo, P Robson, AH Hart, L Trippa, GC Yuan
Proceedings of the National Academy of Sciences 111 (52), E5643-E5650, 2014
Prognostic role of circulating exosomal miRNAs in multiple myeloma.
SM others
Blood 129 (17), 2429--2436, 2017
Adaptive platform trials: definition, design, conduct and reporting considerations
Nature Reviews Drug Discovery 18 (10), 797-807, 2019
On the restricted mean survival time curve in survival analysis
L Zhao, B Claggett, L Tian, H Uno, MA Pfeffer, SD Solomon, L Trippa, ...
Biometrics 72 (1), 215-221, 2016
Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples
M Riester, W Wei, L Waldron, AC Culhane, L Trippa, E Oliva, S Kim, ...
Journal of the National Cancer Institute 106 (5), dju048, 2014
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma
EK O'Donnell, JP Laubach, AJ Yee, T Chen, CA Huff, FG Basile, ...
British journal of haematology 182 (2), 222-230, 2018
Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression
M Bustoros, R Sklavenitis-Pistofidis, J Park, R Redd, B Zhitomirsky, ...
Journal of Clinical Oncology 38 (21), 2380, 2020
Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer
HA Parsons, J Rhoades, SC Reed, G Gydush, P Ram, P Exman, K Xiong, ...
Clinical Cancer Research 26 (11), 2556-2564, 2020
The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?
AM Vanderbeek, R Rahman, G Fell, S Ventz, T Chen, R Redd, ...
Neuro-oncology 20 (8), 1034-1043, 2018
Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab
OM Filho, G Viale, S Stein, L Trippa, DA Yardley, IA Mayer, VG Abramson, ...
Cancer discovery 11 (10), 2474-2487, 2021
Bayesian adaptive randomized trial design for patients with recurrent glioblastoma
L Trippa, EQ Lee, PY Wen, TT Batchelor, T Cloughesy, G Parmigiani, ...
Journal of Clinical Oncology 30 (26), 3258, 2012
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
TH Mouhieddine, AS Sperling, R Redd, J Park, M Leventhal, CJ Gibson, ...
Nature communications 11 (1), 2996, 2020
A comparison of Bayesian adaptive randomization and multi‐stage designs for multi‐arm clinical trials
JMS Wason, L Trippa
Statistics in medicine 33 (13), 2206-2221, 2014
Cross-study validation for the assessment of prediction algorithms
C Bernau, M Riester, AL Boulesteix, G Parmigiani, C Huttenhower, ...
Bioinformatics 30 (12), i105-i112, 2014
Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial
SM Tolaney, N Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, ...
Journal of Clinical Oncology 39 (21), 2375-2385, 2021
Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor–positive, ERBB2-negative metastatic breast cancer: A randomized …
SM Tolaney, R Barroso-Sousa, T Keenan, T Li, L Trippa, I Vaz-Luis, ...
JAMA oncology 6 (10), 1598-1605, 2020
Hazards of hazard ratios—deviations from model assumptions in immunotherapy
BM Alexander, JD Schoenfeld, L Trippa
New England Journal of Medicine 378 (12), 1158-1159, 2018
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.
O Metzger Filho, G Viale, L Trippa, T Li, DA Yardley, IA Mayer, ...
Journal of Clinical Oncology 37 (15_suppl), 502-502, 2019
Progression risk stratification of asymptomatic Waldenström macroglobulinemia
M Bustoros, R Sklavenitis-Pistofidis, P Kapoor, CJ Liu, E Kastritis, ...
Journal of Clinical Oncology 37 (16), 1403, 2019
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20